CYP3A4 Gene (Protein Coding)

Cytochrome P450 Family 3 Subfamily A Member 4

GC07M099759
GIFtS:
48
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzym... See more...

Aliases for CYP3A4 Gene

Aliases for CYP3A4 Gene

  • Cytochrome P450 Family 3 Subfamily A Member 4 2 3 5
  • Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 4 2 3
  • Cytochrome P450, Family 3, Subfamily A, Polypeptide 4 2 3
  • Albendazole Monooxygenase (Sulfoxide-Forming) 3 4
  • 1,4-Cineole 2-Exo-Monooxygenase 3 4
  • 1,8-Cineole 2-Exo-Monooxygenase 3 4
  • Cholesterol 25-Hydroxylase 3 4
  • Albendazole Sulfoxidase 3 4
  • Quinine 3-Monooxygenase 3 4
  • Cytochrome P450 NF-25 3 4
  • Cytochrome P450-PCN1 3 4
  • Cytochrome P450 3A4 3 4
  • Cytochrome P450 3A3 3 4
  • Cytochrome P450 HLp 3 4
  • Nifedipine Oxidase 3 4
  • EC 1.14.14.1 4 51
  • CYPIIIA3 3 4
  • CYPIIIA4 3 4
  • CYP3A3 3 4
  • Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 3 3
  • Taurochenodeoxycholate 6-Alpha-Hydroxylase 3
  • Glucocorticoid-Inducible P450 3
  • P450-III, Steroid Inducible 3
  • Albendazole Monooxygenase 3
  • EC 1.14.14.56 4
  • EC 1.14.14.73 4
  • EC 1.14.14.55 4
  • P450PCN1 3
  • P450C3 3
  • CYP3A4 5
  • CYP3A 3
  • NF-25 3
  • CP33 3
  • CP34 3
  • HLP 3

External Ids for CYP3A4 Gene

Previous HGNC Symbols for CYP3A4 Gene

  • CYP3A3

Previous GeneCards Identifiers for CYP3A4 Gene

  • GC07M097889
  • GC07M098952
  • GC07M098967
  • GC07M098968
  • GC07M098892
  • GC07M098999
  • GC07M099192
  • GC07M099355
  • GC07M093991

Summaries for CYP3A4 Gene

Entrez Gene Summary for CYP3A4 Gene

  • This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs in use today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Previously another CYP3A gene, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Feb 2011]

GeneCards Summary for CYP3A4 Gene

CYP3A4 (Cytochrome P450 Family 3 Subfamily A Member 4) is a Protein Coding gene. Diseases associated with CYP3A4 include Acetaminophen Metabolism and Drug Allergy. Among its related pathways are Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics and Cytochrome P450 - arranged by substrate type. Gene Ontology (GO) annotations related to this gene include enzyme binding and iron ion binding. An important paralog of this gene is CYP3A7.

UniProtKB/Swiss-Prot Summary for CYP3A4 Gene

  • A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:20702771, PubMed:19965576, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:2732228, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:21576599, PubMed:21490593). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:14559847, PubMed:12865317). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:2732228, PubMed:15373842, PubMed:15764715, PubMed:22773874). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:2732228, PubMed:15373842, PubMed:15764715). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850).

Tocris Summary for CYP3A4 Gene

  • Cytochrome P450 (CYP450) enzymes are a diverse group of catalysts that contains 57 members in humans. CYPs are usually membrane-bound and are localized to the inner mitochondrial or endoplasmic reticular membrane. CYPs have oxygenase activity.

Gene Wiki entry for CYP3A4 Gene

PharmGKB "VIP" Summary for CYP3A4 Gene

Additional gene information for CYP3A4 Gene

No data available for CIViC Summary , Rfam classification and piRNA Summary for CYP3A4 Gene

Genomics for CYP3A4 Gene

GeneHancer (GH) Regulatory Elements Pubs

Download GeneHancer 2017 data
Promoters and enhancers for CYP3A4 Gene
GeneHancer (GH) Identifier GH Type GH
Score		 GH Sources Gene Association Score Total Score TSS distance (kb) Number of Genes Away Size (kb) Transcription Factor
Binding Sites		 Gene Targets
GH07J099783 Promoter/Enhancer 0.9 EPDnew ENCODE dbSUPER 600.7 -0.2 -195 2 SP1 RXRA REST TAF1 CYP3A4 ATP5MF PVRIG piR-39341-368 CYP3A43 RF00017-6476
GH07J099782 Enhancer 0.6 Ensembl 600.7 +1.7 1747 0.6 GATAD2A RXRB REST SOX13 CTBP1 DPF2 RXRA RARA THRB RAD21 CYP3A4 piR-61514-175 CYP3A7 CYP3A7-CYP3A51P RF00017-6476
GH07J099797 Promoter 0.3 EPDnew 600.4 -13.0 -12976 0.1 CYP3A4 piR-39341-368 CYP3A43 RF00017-6476
GH07J099692 Enhancer 1.4 FANTOM5 ENCODE dbSUPER 2.1 +90.0 89999 2.7 GATAD2A REST TFE3 ZNF512 RFX1 LEF1 IKZF1 NFKBIZ ZNF692 NFRKB PDAP1 PTCD1 MAP11 CYP3A5 SAP25 ZSCAN25 TMEM225B CYP3A43 CYP3A4 AZGP1
GH07J099791 Enhancer 1.2 FANTOM5 Ensembl ENCODE dbSUPER 0.4 -7.9 -7929 3.6 ATF7 REST IKZF1 ZNF7 SP1 CEBPA CEBPB MGA FOXA2 ATF3 TRIM4 SAP25 CYP3A43 CYP3A5 CYP3A4 piR-39341-368 RF00017-6476
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around CYP3A4 on the GeneHancer Hub at the UCSC Golden Path

Cistromic (ChIP-Seq) regulation report from SPP (The Signaling Pathways Project) for CYP3A4

Top Transcription factor binding sites by QIAGEN in the CYP3A4 gene promoter:
  • COUP
  • COUP-TF
  • COUP-TF1
  • GATA-6
  • GR
  • GR-alpha
  • HNF-4alpha1
  • HNF-4alpha2
  • NF-kappaB1
  • STAT3

Genomic Locations for CYP3A4 Gene

Genomic Locations for CYP3A4 Gene
chr7:99,756,960-99,784,248
(GRCh38/hg38)
Size:
27,289 bases
Orientation:
Minus strand
chr7:99,354,583-99,381,888
(GRCh37/hg19)
Size:
27,306 bases
Orientation:
Minus strand

Genomic View for CYP3A4 Gene

Genes around CYP3A4 on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
CYP3A4 Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for CYP3A4 Gene
GeneLoc Logo Genomic Neighborhood • Exon Structure • Gene Density

RefSeq DNA sequence for CYP3A4 Gene

Proteins for CYP3A4 Gene

Products:

  1. Antibody
  2. Protein
  3. Assay

  • Protein details for CYP3A4 Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    P08684-CP3A4_HUMAN
    Recommended name:
    Cytochrome P450 3A4
    Protein Accession:
    P08684
    Secondary Accessions:
    • P05184
    • Q16757
    • Q9UK50

    Protein attributes for CYP3A4 Gene

    Size:
    503 amino acids
    Molecular mass:
    57343 Da
    Cofactor:
    Name=heme; Xref=ChEBI:CHEBI:30413;
    Quaternary structure:
    • Interacts with PGRMC1; the interaction requires PGRMC1 homodimerization.
    Miscellaneous:
    • Chimeric transcripts, characterized by CYP3A43 exon 1 joined at canonical splice sites to distinct sets of CYP3A4 exons, have been detected. All are possibly produced by trans-splicing. The chimeric transcripts exist in 3 different combinations: CYP3A43 exon 1 joined in frame to CYP3A4 exons 2-13, CYP3A43 exon 1 joined in frame to CYP3A4 exons 4-13 and CYP3A43 exon 1 joined in frame to CYP3A4 exon 7-13. The longest chimeric isoform (CYP3A43 exon 1 joined to CYP3A4 exons 2-13) exhibits 6-beta-hydroxylase activity, while a shorter isoform (CYP3A43 exon 1 joined to CYP3A4 exons 4-13) does not. All chimeric transcripts are expressed at very low levels in the liver (PubMed:11726664).

    Three dimensional structures from OCA and Proteopedia for CYP3A4 Gene

neXtProt entry for CYP3A4 Gene

Protein Expression for CYP3A4 Gene

See protein expression from ProteomicsDB, MOPED, PaxDb, and MaxQB

Selected DME Specific Peptides for CYP3A4 Gene

P08684:
  • VLVKECYSVFTN
  • LVLLYLYGT
  • PGPTPLP
  • PCKETQIPLK
  • QPVLAIT
  • SVFTNRR
  • PNKAPPTYD
  • RVDFLQLM
  • LLSPTFT
  • LSPTFTSG
  • PTFTSGK
  • NIDPYIY
  • DFLQLMIDSQ
  • SHKALSD
  • PERFSKKN

Post-translational modifications for CYP3A4 Gene

  • Polyubiquitinated in the presence of AMFR and UBE2G1 and also STUB1/CHIP and UBE2D1 (in vitro).
  • Modification sites at PhosphoSitePlus
  • Modification sites at neXtProt

Other Protein References for CYP3A4 Gene

ENSEMBL proteins:
REFSEQ proteins:

Antibody Products

Domains & Families for CYP3A4 Gene

Gene Families for CYP3A4 Gene

HGNC:
IUPHAR :
Human Protein Atlas (HPA):
  • Cancer-related genes
  • Enzymes
  • Plasma proteins
  • Predicted intracellular proteins
  • Predicted membrane proteins

Protein Domains for CYP3A4 Gene

InterPro:
Blocks:
  • E-class P450 group I signature
  • Group II E-class P450 signature
  • CYP3A P450 family signature
ProtoNet:

Suggested Antigen Peptide Sequences for CYP3A4 Gene

GenScript: Design optimal peptide antigens:
  • Taurochenodeoxycholate 6-alpha-hydroxylase (CP3A4_HUMAN)
  • cDNA, FLJ93427, Homo sapiens cytochrome P450, family 3, subfamily A, polypeptide 4(CYP3A4), transcript variant 1, mRNA (Q6GRK0_HUMAN)
  • Cytochrome P450 (Q7Z448_HUMAN)

Graphical View of Domain Structure for InterPro Entry

P08684

UniProtKB/Swiss-Prot:

CP3A4_HUMAN :
  • Belongs to the cytochrome P450 family.
Family:
  • Belongs to the cytochrome P450 family.
genes like me logo Genes that share domains with CYP3A4: view

Function for CYP3A4 Gene

Products:

  1. Animal Model
  2. CRISPR
  3. miRNA
  4. Inhibitory RNA
  5. Clone
  6. Cell Line

Molecular function for CYP3A4 Gene

UniProtKB/Swiss-Prot Function:
A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:20702771, PubMed:19965576, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:2732228, PubMed:14559847, PubMed:12865317, PubMed:15373842, PubMed:15764715, PubMed:21576599, PubMed:21490593). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:14559847, PubMed:12865317). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:2732228, PubMed:15373842, PubMed:15764715, PubMed:22773874). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:2732228, PubMed:15373842, PubMed:15764715). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850).
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=an organic molecule + O2 + reduced [NADPH--hemoprotein reductase] = an alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17149, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30879, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:142491; EC=1.14.14.1; Evidence={ECO:0000269|PubMed:11555828, ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:2732228, ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxy-17beta-estradiol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47212, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:28744, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:11555828, ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 4-hydroxy-17beta-estradiol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47280, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:62845; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 16alpha,17beta-estriol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47332, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:27974, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:14559847};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 16beta,17beta-estriol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47336, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:87620; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=estrone + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxyestrone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47208, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:1156, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17263, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=estrone + O2 + reduced [NADPH--hemoprotein reductase] = 4-hydroxyestrone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47292, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17263, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:87602; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=estrone + O2 + reduced [NADPH--hemoprotein reductase] = 16alpha-hydroxyestrone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47204, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:776, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17263, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:14559847};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + reduced [NADPH--hemoprotein reductase] + testosterone = 1beta-hydroxytestosterone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53260, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17347, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:137076; Evidence={ECO:0000269|PubMed:15373842};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + reduced [NADPH--hemoprotein reductase] + testosterone = 2beta-hydroxytestosterone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53264, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17347, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:137077; Evidence={ECO:0000269|PubMed:15373842};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + reduced [NADPH--hemoprotein reductase] + testosterone = 6beta,17beta-dihydroxyandrost-4-en-3-one + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:46296, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17347, ChEBI:CHEBI:34477, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:15764715, ECO:0000269|PubMed:20702771, ECO:0000269|PubMed:2732228};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + reduced [NADPH--hemoprotein reductase] + testosterone = 11beta,17beta-dihydroxyandrost-4-ene-3-one + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53444, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17347, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:81481; Evidence={ECO:0000269|PubMed:15764715};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-hydroxy-5alpha-androstan-3-one + O2 + reduced [NADPH--hemoprotein reductase] = 17beta,18-dihydroxy-3-oxo-5alpha-androstanone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53212, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16330, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:137037; Evidence={ECO:0000269|PubMed:22773874};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-hydroxy-5alpha-androstan-3-one + O2 + reduced [NADPH--hemoprotein reductase] = 17beta,19-dihydroxy-3-oxo-5alpha-androstanone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53200, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16330, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:137031; Evidence={ECO:0000269|PubMed:22773874};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=androst-4-ene-3,17-dione + O2 + reduced [NADPH--hemoprotein reductase] = 6beta-hydroxyandrost-4-ene-3,17-dione + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47256, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16422, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:87571; Evidence={ECO:0000269|PubMed:2732228};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + progesterone + reduced [NADPH--hemoprotein reductase] = 6beta-hydroxyprogesterone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47252, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17026, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:62117; Evidence={ECO:0000269|PubMed:2732228};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + progesterone + reduced [NADPH--hemoprotein reductase] = 16alpha-hydroxyprogesterone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47260, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15826, ChEBI:CHEBI:17026, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:2732228};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cortisone + O2 + reduced [NADPH--hemoprotein reductase] = 6beta-hydroxycortisone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:55832, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16962, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:139269; Evidence={ECO:0000269|PubMed:21490593};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cortisol + O2 + reduced [NADPH--hemoprotein reductase] = 6beta-hydroxycortisol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:55828, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17650, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:139271; Evidence={ECO:0000269|PubMed:21490593};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 25-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50256, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:42977, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:21576599};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 4beta-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:46128, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:85778; Evidence={ECO:0000269|PubMed:21576599};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 22R-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:46140, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:67237; Evidence={ECO:0000269|PubMed:21576599};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = (24R)-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:46144, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:50516, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:21576599};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 26-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50264, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:17703, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:21576599};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9Z,12Z)-octadecadienoate + O2 + reduced [NADPH--hemoprotein reductase] = 11-hydroxy-(9Z,12Z)-octadecadienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52284, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30245, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136522; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 7-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52288, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136523; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 10-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52296, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:133345; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 13-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52292, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136524; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49860, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131965; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49856, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131964; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = (17R,18S)-epoxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39779, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76634; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 + reduced [NADPH--hemoprotein reductase] = (19R,20S)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52120, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77016, ChEBI:CHEBI:136410; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 + reduced [NADPH--hemoprotein reductase] = (19S,20R)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52124, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77016, ChEBI:CHEBI:136411; Evidence={ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + O2 + reduced [NADPH--hemoprotein reductase] = H(+) + H2O + N-(8,9-epoxy-5Z,11Z,14Z-eicosatrienoyl)-ethanolamine + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53140, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:2700, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136989; Evidence={ECO:0000269|PubMed:20702771};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + O2 + reduced [NADPH--hemoprotein reductase] = H(+) + H2O + N-(11,12-epoxy-5Z,8Z,14Z-eicosatrienoyl)-ethanolamine + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53144, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:2700, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136990; Evidence={ECO:0000269|PubMed:20702771};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + O2 + reduced [NADPH--hemoprotein reductase] = H(+) + H2O + N-(14,15-epoxy-5Z,8Z,11Z-eicosatrienoyl)-ethanolamine + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53148, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:2700, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136991; Evidence={ECO:0000269|PubMed:20702771};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=all-trans-retinol + O2 + reduced [NADPH--hemoprotein reductase] = all-trans-retinal + H(+) + 2 H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:42092, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17336, ChEBI:CHEBI:17898, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:10681376};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=all-trans-retinoate + O2 + reduced [NADPH--hemoprotein reductase] = all-trans-4-hydroxyretinoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:51984, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:35291, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:134178; Evidence={ECO:0000269|PubMed:11093772};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + quinine + reduced [NADPH--hemoprotein reductase] = 3-hydroxyquinine + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:20149, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58234, ChEBI:CHEBI:137041; EC=1.14.14.55; Evidence={ECO:0000269|PubMed:8968357};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=fenbendazole + O2 + reduced [NADPH--hemoprotein reductase] = fenbendazole S-oxide + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:55928, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:35812, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77092; EC=1.14.14.73; Evidence={ECO:0000269|PubMed:10759686};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=albendazole + O2 + reduced [NADPH--hemoprotein reductase] = albendazole S-oxide + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:55924, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16664, ChEBI:CHEBI:16959, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.73; Evidence={ECO:0000269|PubMed:10759686};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=1,8-cineole + O2 + reduced [NADPH--hemoprotein reductase] = 2-exo-hydroxy-1,8-cineole + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:32895, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16271, ChEBI:CHEBI:27961, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.56; Evidence={ECO:0000269|PubMed:11159812};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=1,4-cineole + O2 + reduced [NADPH--hemoprotein reductase] = 2-exo-hydroxy-1,4-cineole + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49160, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:80788, ChEBI:CHEBI:90956; Evidence={ECO:0000269|PubMed:11695850};.
UniProtKB/Swiss-Prot Induction:
By drugs, such as rifampicin.
UniProtKB/Swiss-Prot BiophysicochemicalProperties:
Kinetic parameters: KM=52.16 uM for 17beta-estradiol (2-hydroxylation) {ECO:0000269|PubMed:12865317}; KM=53.88 uM for 17beta-estradiol (4-hydroxylation) {ECO:0000269|PubMed:12865317}; KM=7.69 uM for estrone (2-hydroxylation) {ECO:0000269|PubMed:12865317}; KM=7.18 uM for estrone (4-hydroxylation) {ECO:0000269|PubMed:12865317}; KM=17 uM for testosterone (1beta-hydroxylation) {ECO:0000269|PubMed:15373842}; KM=44 uM for testosterone (2beta-hydroxylation) {ECO:0000269|PubMed:15373842}; KM=23 uM for testosterone (6beta-hydroxylation) {ECO:0000269|PubMed:15373842}; KM=32 uM for testosterone (15beta-hydroxylation) {ECO:0000269|PubMed:15373842}; KM=182 uM for cholesterol (25-hydroxylation) {ECO:0000269|PubMed:21576599}; KM=62 uM for cholesterol (4beta-hydroxylation) {ECO:0000269|PubMed:21576599}; KM=37 uM for cholesterol (22R-hydroxylation) {ECO:0000269|PubMed:21576599}; KM=161 uM for cholesterol (24R-hydroxylation) {ECO:0000269|PubMed:21576599}; KM=15 uM for cholesterol (24S-hydroxylation) {ECO:0000269|PubMed:21576599}; KM=80 uM for cholesterol (26-hydroxylation) {ECO:0000269|PubMed:21576599}; KM=118 uM for anandamide (epoxidation across positions 5 and 6) {ECO:0000269|PubMed:20702771}; KM=48 uM for anandamide (epoxidation across positions 8 and 9) {ECO:0000269|PubMed:20702771}; KM=118 uM for anandamide (epoxidation across positions 11 and 12) {ECO:0000269|PubMed:20702771}; KM=80 uM for anandamide (epoxidation across positions 14 and 15) {ECO:0000269|PubMed:20702771}; KM=25 uM for all-trans retinol {ECO:0000269|PubMed:10681376}; KM=34 uM for all-trans-retinoate (4-hydroxylation) {ECO:0000269|PubMed:11093772}; KM=89 uM for cortisone (6beta-hydroxylation) {ECO:0000269|PubMed:21490593}; KM=148 uM for cortisol (6beta-hydroxylation) {ECO:0000269|PubMed:21490593}; KM=114.4 uM for quinine {ECO:0000269|PubMed:8968357}; KM=450 uM for 1,4-cineole {ECO:0000269|PubMed:11695850}; Vmax=1020 pmol/min/nmol enzyme toward 17beta-estradiol (2-hydroxylation) {ECO:0000269|PubMed:12865317}; Vmax=448.5 pmol/min/nmol enzyme toward 17beta-estradiol (4-hydroxylation) {ECO:0000269|PubMed:12865317}; Vmax=167.5 pmol/min/nmol enzyme toward estrone (2-hydroxylation) {ECO:0000269|PubMed:12865317}; Vmax=79.5 pmol/min/nmol enzyme toward estrone (4-hydroxylation) {ECO:0000269|PubMed:12865317}; Vmax=42 pmol/min/nmol enzyme toward cholesterol (25-hydroxylation) {ECO:0000269|PubMed:21576599}; Vmax=12 pmol/min/nmol enzyme toward cholesterol (4beta-hydroxylation) {ECO:0000269|PubMed:21576599}; Vmax=3.42 pmol/min/nmol enzyme toward cholesterol (22R-hydroxylation) {ECO:0000269|PubMed:21576599}; Vmax=3.48 pmol/min/nmol enzyme toward cholesterol (24R-hydroxylation) {ECO:0000269|PubMed:21576599}; Vmax=0.2 pmol/min/nmol enzyme toward cholesterol (24S-hydroxylation) {ECO:0000269|PubMed:21576599}; Vmax=3.18 pmol/min/nmol enzyme toward cholesterol (26-hydroxylation) {ECO:0000269|PubMed:21576599}; Vmax=225 pmol/min/nmol enzyme toward all-trans retinol {ECO:0000269|PubMed:10681376}; Vmax=195 pmol/min/nmol enzyme toward all-trans-retinoate (4-hydroxylation) {ECO:0000269|PubMed:11093772}; Vmax=15 pmol/min/pmol enzyme toward cortisone (6beta-hydroxylation) {ECO:0000269|PubMed:21490593}; Vmax=27 pmol/min/pmol enzyme toward cortisol (6beta-hydroxylation) {ECO:0000269|PubMed:21490593}; Vmax=7.49 pmol/min/pmol enzyme toward quinine {ECO:0000269|PubMed:8968357}; Vmax=7.5 nmol/min/nmol enzyme toward 1,4-cineole {ECO:0000269|PubMed:11695850};
UniProtKB/Swiss-Prot EnzymeRegulation:
Activated by cytochrome b5.
GENATLAS Biochemistry:
cytochrome P450,family III,polypeptide 4 (niphedipine oxidase);highly expressed in the liver,see CYP3A@,with a significant association of the wild type enzyme with epipodophyllotoxin-induced leukemogenesis

Enzyme Numbers (IUBMB) for CYP3A4 Gene

Phenotypes From GWAS Catalog for CYP3A4 Gene

Gene Ontology (GO) - Molecular Function for CYP3A4 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0004497 monooxygenase activity IEA,ISS --
GO:0005496 steroid binding IDA 15256616
GO:0005506 iron ion binding IEA,IDA 15256616
GO:0005515 protein binding IPI 26988023
GO:0008395 steroid hydroxylase activity IMP 18356043
genes like me logo Genes that share ontologies with CYP3A4: view
genes like me logo Genes that share phenotypes with CYP3A4: view

CRISPR Products

miRNA for CYP3A4 Gene

miRTarBase miRNAs that target CYP3A4

Inhibitory RNA Products

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP3A4

No data available for Human Phenotype Ontology , Animal Models , Transcription Factor Targets and HOMER Transcription for CYP3A4 Gene

Localization for CYP3A4 Gene

Subcellular locations from UniProtKB/Swiss-Prot for CYP3A4 Gene

Endoplasmic reticulum membrane. Single-pass membrane protein. Microsome membrane. Single-pass membrane protein.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for CYP3A4 gene
Compartment Confidence
endoplasmic reticulum 5
plasma membrane 3
extracellular 3
nucleus 3
cytosol 3
cytoskeleton 2
mitochondrion 2
peroxisome 2
lysosome 2
endosome 1
golgi apparatus 1

Subcellular locations from the

Human Protein Atlas (HPA)
  • Cytosol (1)
See all subcellular structures

Gene Ontology (GO) - Cellular Components for CYP3A4 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0005737 cytoplasm IDA 18446064
GO:0005783 endoplasmic reticulum IEA --
GO:0005789 endoplasmic reticulum membrane TAS --
GO:0016020 membrane IEA --
GO:0016021 integral component of membrane IEA --
genes like me logo Genes that share ontologies with CYP3A4: view

Pathways & Interactions for CYP3A4 Gene

PathCards logo

SuperPathways for CYP3A4 Gene

SuperPathway Contained pathways
1 Drug metabolism - cytochrome P450
Drug metabolism - cytochrome P450
.71
Metabolism of xenobiotics by cytochrome P450
.71
Chemical carcinogenesis
.68
Drug metabolism - other enzymes
.37
Retinol metabolism
.32
Retinol metabolism
.31
Artemisinin and Derivatives Pathway, Pharmacokinetics
.01
Benzodiazepine Pathway, Pharmacokinetics
.01
Celecoxib Pathway, Pharmacokinetics
.01
Fluoxetine Pathway, Pharmacokinetics
.01
Haloperidol Pathway, Pharmacokinetics
.01
Ifosfamide Pathway, Pharmacokinetics
.01
Sertraline Pathway, Pharmacokinetics
.01
Voriconazole Pathway, Pharmacokinetics
.01
Benzo[a]pyrene metabolism
.01
Aflatoxin B1 metabolism
.01
2 Imipramine/Desipramine Pathway, Pharmacokinetics
Imipramine/Desipramine Pathway, Pharmacokinetics
.57
Paroxetine Pathway, Pharmacokinetics
.57
Verapamil Pathway, Pharmacokinetics
.56
Amitriptyline and Nortriptyline Pathway, Pharmacokinetics
.50
Olanzapine Pathway, Pharmacokinetics
.50
Venlafaxine Pathway, Pharmacokinetics
.44
Warfarin Pathway, Pharmacokinetics
.40
Clozapine Pathway, Pharmacokinetics
.38
Nevirapine Pathway, Pharmacokinetics
.30
Citalopram Pathway, Pharmacokinetics
.01
Clomipramine Pathway, Pharmacokinetics
.01
Doxepin Pathway, Pharmacokinetics
.01
Metoprolol Pathway, Pharmacokinetics
.01
Proton Pump Inhibitor Pathway, Pharmacokinetics
.01
Colchicine Metabolic Pathway
.01
Lidocaine metabolism
.01
3 Cytochrome P450 - arranged by substrate type
Cytochrome P450 - arranged by substrate type
.64
Oxidation by Cytochrome P450
.64
Phase 1 - Functionalization of compounds
.63
Biological oxidations
.49
Xenobiotics
.39
Metapathway biotransformation
.36
Lidocaine Pathway, Pharmacokinetics
.01
Estradiol metabolism
.01
Vitamin D2 (ergocalciferol) metabolism
.01
Benzo(a)pyrene metabolism
.01
Fatty Acid Omega Oxidation
.01
4 Carvedilol Pathway, Pharmacokinetics
Carvedilol Pathway, Pharmacokinetics
.46
Codeine and Morphine Metabolism
.46
Codeine and Morphine Pathway, Pharmacokinetics
.41
Macrolide Antibiotic Pathway, Pharmacokinetics/Pharmacodynamics
.40
Ivacaftor pathway, pharmacokinetics/pharmacodynamics
.38
Tramadol Pharmacokinetics
.36
Losartan Pathway, Pharmacokinetics
.33
Clopidogrel Pathway, Pharmacokinetics
.31
Oxycodone Pathway, Pharmacokinetics
.01
Tacrolimus/Cyclosporine Pathway, Pharmacokinetics
.01
5 Statin Pathway - Generalized, Pharmacokinetics
Ibuprofen Pathway, Pharmacokinetics
.42
Statin Pathway - Generalized, Pharmacokinetics
.42
Diclofenac Pathway, Pharmacokinetics
.39
Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
.01
Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics
.01
Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
.01
Clobazam Pathway, Pharmacokinetics
.01
Fluvastatin Pathway, Pharmacokinetics
.01
genes like me logo Genes that share pathways with CYP3A4: view

UniProtKB/Swiss-Prot P08684-CP3A4_HUMAN

  • Pathway: Steroid hormone biosynthesis.
  • Pathway: Cofactor metabolism; retinol metabolism.
  • Pathway: Steroid metabolism; cholesterol metabolism.
  • Pathway: Lipid metabolism; fatty acid metabolism.

SIGNOR curated interactions for CYP3A4 Gene

Is activated by:
Is inactivated by:

Gene Ontology (GO) - Biological Process for CYP3A4 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0002933 lipid hydroxylation IDA 14559847
GO:0006629 lipid metabolic process TAS 2492107
GO:0006631 fatty acid metabolic process IEA --
GO:0006694 steroid biosynthetic process IEA --
GO:0006706 steroid catabolic process IMP 18356043
genes like me logo Genes that share ontologies with CYP3A4: view

Drugs & Compounds for CYP3A4 Gene

Products:

  1. Drug

(1159) Drugs for CYP3A4 Gene - From: DrugBank, PharmGKB, ClinicalTrials, ApexBio, DGIdb, HMDB, Tocris, and Novoseek

Name Status Disease Links Group Role Mechanism of Action Clinical Trials
Ketoconazole Approved, Investigational Pharma Pore Blocker, Enzyme, substrate, inhibitor Inhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase, Cytochrome P450c17 inhibitor 194
Carbamazepine Approved, Investigational Pharma Enzyme, substrate, inducer Inhibitor of neuronal voltage-gated Na+ channels; anticonvulsant 104
Clarithromycin Approved Pharma Enzyme, substrate, inhibitor 379
Clopidogrel Approved Pharma Enzyme, substrate P2Y12 receptor antagonist 934
Midazolam Approved, Illicit Pharma Enzyme, substrate, inhibitor 1043

(101) Additional Compounds for CYP3A4 Gene - From: HMDB and Novoseek

Name Synonyms Role CAS Number PubChem IDs PubMed IDs
3-Hydroxyquinine
  • 3-Hydroxyquinidine
  • 6'-Methoxycinchonan-3,9-diol
  • 3-Hydroxyquinidine, (3alpha,9S)-isomer
  • 3-Hydroxyquinidine, (8alpha,9R)-isomer
 53467-23-5
Paraxanthine
  • 3,7-dihydro-1,7-Dimethyl-1H-purine-2,6-dione
  • P-Xanthine
  • 1,7-Dimethyl-xanthine
  • 1,7-Dimethylxanthine
 611-59-6
11,12,15-THETA
  • 11,12,15-Trihydroxyicosatrienoic acid
  • (5Z,8Z,13E)-(15S)-11,12,15-Trihydroxyeicosa-5,8,12-trienoic acid
  • (5Z,8Z,13E)-(15S)-11,12,15-Trihydroxyicosa-5,8,12-trienoic acid
  • 11,12,15-Trihydroxyicosatrienoate
  • (5Z,8Z,13E)-(15S)-11,12,15-Trihydroxyeicosa-5,8,12-trienoate
11,12-EpETrE
  • (+/-)11(12)-eet
  • (+/-)11(12)-epetre
  • (+/-)11,12-epetre
  • (5Z,8Z,14Z)-11,12-Epoxyeicosa-5,8,14-trienoate
  • (5Z,8Z,14Z)-11,12-Epoxyeicosa-5,8,14-trienoic acid
 81276-02-0
11,14,15-THETA
  • 11,14,15-Trihydroxyicosatrienoic acid
  • (5Z,8Z,12E)-11,14,15-Trihydroxyeicosa-5,8,12-trienoic acid
  • (5Z,8Z,12E)-11,14,15-Trihydroxyicosa-5,8,12-trienoic acid
  • 11,14,15-Trihydroxyicosatrienoate
  • (5Z,8Z,12E)-11,14,15-Trihydroxyeicosa-5,8,12-trienoate

(5) Tocris Compounds for CYP3A4 Gene

Compound Action Cas Number
Anastrozole Potent aromatase (CYP19) inhibitor 120511-73-1
Exemestane Steroidal aromatase (CYP19) inhibitor 107868-30-4
Ketoconazole Cytochrome P450c17 inhibitor 65277-42-1
TMS Cytochrome P450 1B1 inhibitor 24144-92-1
YM 511 Potent aromatase (CYP19) inhibitor 148869-05-0

(14) ApexBio Compounds for CYP3A4 Gene

Compound Action Cas Number
(+)-Ketoconazole 142128-59-4
8-Methoxypsoralen CYP inhibitor 298-81-7
ABT 1614-12-6
Alizarin Biological stain 72-48-0
Amiodarone HCl Anti-arrhythmic drug 19774-82-4
Clarithromycin 81103-11-9
Cobicistat (GS-9350) Selective CYP3A inhibitor 1004316-88-4
Ketoconazole Inhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase 65277-42-1
Pentoxyresorufin 87687-03-4
PF-4981517 CYP3A4 inhibitor,potent and selective 1390637-82-7
Posaconazole Sterol C14ɑ demethylase inhibitor 171228-49-2
Posaconazole hydrate C14ɑ demethylase inhibitor 1198769-38-8
TMS 24144-92-1
YM 511 148869-05-0
genes like me logo Genes that share compounds with CYP3A4: view

Drug Products

Transcripts for CYP3A4 Gene

Products:

  1. CRISPR
  2. miRNA
  3. Inhibitory RNA
  4. Clone

mRNA/cDNA for CYP3A4 Gene

4 REFSEQ mRNAs :
16 NCBI additional mRNA sequence :
8 Ensembl transcripts including schematic representations, and UCSC links to gene/alias where relevant :

CRISPR Products

Inhibitory RNA Products

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP3A4

Alternative Splicing Database (ASD) splice patterns (SP) for CYP3A4 Gene

No ASD Table

Relevant External Links for CYP3A4 Gene

GeneLoc Exon Structure for
CYP3A4

Expression for CYP3A4 Gene

Products:

  1. Primer
  2. Gene Expression Assay

mRNA expression in normal human tissues from GTEx, Illumina, BioGPS, and SAGE for CYP3A4 Gene

mRNA expression in normal human tissues for CYP3A4 Gene
mRNA expression by BioGPS for CYP3A4 GenemRNA expression by GTEx for CYP3A4 Gene

mRNA differential expression in normal tissues according to GTEx for CYP3A4 Gene

This gene is overexpressed in Liver (x43.8) and Small Intestine - Terminal Ileum (x6.9).

Protein differential expression in normal tissues from HIPED for CYP3A4 Gene

This gene is overexpressed in Gallbladder (35.3), Liver (24.7), and Fetal Liver (7.9).

Integrated Proteomics: protein expression in normal tissues and cell lines from ProteomicsDB and MOPED for CYP3A4 Gene



Protein tissue co-expression partners for CYP3A4 Gene

Transcriptomic regulation report from SPP (The Signaling Pathways Project) for CYP3A4

SOURCE GeneReport for Unigene cluster for CYP3A4 Gene:

Hs.728751

mRNA Expression by UniProt/SwissProt for CYP3A4 Gene:

P08684-CP3A4_HUMAN
Tissue specificity: Expressed in prostate and liver. According to some authors, it is not expressed in brain (PubMed:19094056). According to others, weak levels of expression are measured in some brain locations (PubMed:19359404 and PubMed:18545703). Also expressed in epithelium of the small intestine and large intestine, bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).

Evidence on tissue expression from TISSUES for CYP3A4 Gene

  • Liver(5)
  • Blood(3.6)
  • Intestine(3.3)
  • Urine(3.2)
  • Nervous system(3.1)
  • Kidney(3.1)
  • Skin(2.7)
  • Heart(2.6)
  • Adrenal gland(2.6)
  • Muscle(2.4)
  • Stomach(2.4)
  • Bone marrow(2.2)
  • Thyroid gland(2.2)
  • Pancreas(2.1)
  • Spleen(2)
  • Lung(2)
genes like me logo Genes that share expression patterns with CYP3A4: view

No data available for Phenotype-based relationships between genes and organs from Gene ORGANizer for CYP3A4 Gene

Orthologs for CYP3A4 Gene

This gene was present in the common ancestor of animals.

Orthologs for CYP3A4 Gene

Organism Taxonomy Gene Similarity Type Details
Chimpanzee
(Pan troglodytes)
 Mammalia CYP3A4 30 31
  • 99.4 (n)
 OneToOne
Dog
(Canis familiaris)
 Mammalia CYP3A4 30
  • 84.56 (n)
CYP3A12 31
  • 81 (a)
 ManyToMany
CYP3A26 31
  • 78 (a)
 ManyToMany
-- 31
  • 77 (a)
 ManyToMany
-- 31
  • 76 (a)
 ManyToMany
Cow
(Bos Taurus)
 Mammalia CYP3A5 30 31 31
  • 82.64 (n)
 ManyToMany
-- 31
  • 77 (a)
 ManyToMany
Rat
(Rattus norvegicus)
 Mammalia Cyp3a2 30
  • 77.2 (n)
Mouse
(Mus musculus)
 Mammalia Cyp3a13 31
  • 75 (a)
 ManyToMany
Cyp3a11 31
  • 73 (a)
 ManyToMany
Cyp3a25 31
  • 71 (a)
 ManyToMany
Cyp3a41a 31
  • 71 (a)
 ManyToMany
Cyp3a41b 31
  • 71 (a)
 ManyToMany
Cyp3a16 31
  • 70 (a)
 ManyToMany
Cyp3a44 31
  • 69 (a)
 ManyToMany
Cyp3a59 31
  • 69 (a)
 ManyToMany
Cyp3a57 31
  • 68 (a)
 ManyToMany
Oppossum
(Monodelphis domestica)
 Mammalia -- 31
  • 67 (a)
 ManyToMany
-- 31
  • 66 (a)
 ManyToMany
-- 31
  • 65 (a)
 ManyToMany
-- 31
  • 57 (a)
 ManyToMany
Platypus
(Ornithorhynchus anatinus)
 Mammalia -- 31
  • 56 (a)
 ManyToMany
-- 31
  • 55 (a)
 ManyToMany
-- 31
  • 53 (a)
 ManyToMany
Chicken
(Gallus gallus)
 Aves CYP3A4 30
  • 63.04 (n)
CYP3A37 31
  • 58 (a)
 OneToMany
Lizard
(Anolis carolinensis)
 Reptilia -- 31
  • 60 (a)
 ManyToMany
-- 31
  • 52 (a)
 ManyToMany
Tropical Clawed Frog
(Silurana tropicalis)
 Amphibia LOC100487054 30
  • 60.78 (n)
African clawed frog
(Xenopus laevis)
 Amphibia MGC68821 30
Zebrafish
(Danio rerio)
 Actinopterygii cyp3a65 31
  • 54 (a)
 ManyToMany
cyp3c1l2 31
  • 51 (a)
 ManyToMany
si:dkey-21n8.3 31
  • 49 (a)
 ManyToMany
cyp3c1 31
  • 48 (a)
 ManyToMany
cyp3c4 31
  • 48 (a)
 ManyToMany
Rainbow Trout
(Oncorhynchus mykiss)
 Actinopterygii Omy.6641 30
African malaria mosquito
(Anopheles gambiae)
 Insecta AgaP_AGAP012293 30
  • 48.95 (n)
Fruit Fly
(Drosophila melanogaster)
 Insecta Cyp9f2 30 32
  • 47.35 (n)
Cyp6a23 32
  • 35 (a)
Cyp6a17 32
  • 34 (a)
Cyp6a14 32
  • 33 (a)
Cyp6d4 32
  • 33 (a)
Cyp6g1 32
  • 33 (a)
Cyp6a13 32
  • 32 (a)
Cyp6a2 32
  • 32 (a)
Cyp6a22 32
  • 32 (a)
Cyp6v1 32
  • 32 (a)
Cyp9b2 32
  • 32 (a)
Cyp6a18 32
  • 31 (a)
Cyp6a19 32
  • 31 (a)
Cyp6a20 32
  • 31 (a)
Cyp6a9 32
  • 31 (a)
Cyp6d5 32
  • 31 (a)
Cyp9c1 32
  • 31 (a)
Cyp28d2 32
  • 30 (a)
Cyp6a21 32
  • 30 (a)
Cyp6a8 32
  • 30 (a)
Cyp6g2 32
  • 30 (a)
Cyp6w1 32
  • 30 (a)
Cyp9h1 32
  • 30 (a)
Cyp6d2 32
  • 29 (a)
Cyp28d1 32
  • 27 (a)
Cyp313a1 32
  • 27 (a)
Cyp6t3 32
  • 27 (a)
Cyp9b1 32
  • 27 (a)
Cyp6t1 32
  • 26 (a)
Cyp6u1 32
  • 26 (a)
Cyp28c1 32
  • 25 (a)
Cyp309a2 32
  • 25 (a)
Cyp313a2 32
  • 25 (a)
Cyp28a5 32
  • 24 (a)
Cyp309a1 32
  • 24 (a)
Cyp317a1 32
  • 24 (a)
Worm
(Caenorhabditis elegans)
 Secernentea cyp-25A1 30
  • 46.71 (n)
F14F7.3 32
  • 32 (a)
C36A4.1 32
  • 31 (a)
F14F7.2 32
  • 31 (a)
C36A4.2 32
  • 30 (a)
T10B9.1 32
  • 30 (a)
T10B9.2 32
  • 30 (a)
T10B9.5 32
  • 30 (a)
T10B9.7 32
  • 30 (a)
T10B9.3 32
  • 29 (a)
T10B9.8 32
  • 29 (a)
C36A4.6 32
  • 28 (a)
F42A6.4 32
  • 28 (a)
ZK1320.4 32
  • 26 (a)
K06G5.2 32
  • 25 (a)
Species where no ortholog for CYP3A4 was found in the sources mined by GeneCards:
  • A. gosspyii yeast (Eremothecium gossypii)
  • Actinobacteria (Mycobacterium tuberculosis)
  • Alicante grape (Vitis vinifera)
  • Alpha proteobacteria (Wolbachia pipientis)
  • Amoeba (Dictyostelium discoideum)
  • Archea (Pyrococcus horikoshii)
  • Baker's yeast (Saccharomyces cerevisiae)
  • Barley (Hordeum vulgare)
  • Beta proteobacteria (Neisseria meningitidis)
  • Bread mold (Neurospora crassa)
  • Chromalveolata (Phytophthora infestans)
  • Common water flea (Daphnia pulex)
  • Corn (Zea mays)
  • E. coli (Escherichia coli)
  • Filamentous fungi (Aspergillus nidulans)
  • Firmicute Bacteria (Streptococcus pneumoniae)
  • Fission Yeast (Schizosaccharomyces pombe)
  • Green Algae (Chlamydomonas reinhardtii)
  • Honey Bee (Apis mellifera)
  • K. Lactis Yeast (Kluyveromyces lactis)
  • Loblloly Pine (Pinus taeda)
  • Malaria Parasite (Plasmodium falciparum)
  • Medicago Trunc (Medicago Truncatula)
  • Moss (Physcomitrella patens)
  • Orangutan (Pongo pygmaeus)
  • Pig (Sus scrofa)
  • Rice (Oryza sativa)
  • Rice Blast Fungus (Magnaporthe grisea)
  • Schistosome Parasite (Schistosoma mansoni)
  • Sea Anemone (Nematostella vectensis)
  • Sea Vase (Ciona intestinalis)
  • Sea Squirt (Ciona savignyi)
  • Sea Urchin (Strongylocentrotus purpuratus)
  • Sorghum (Sorghum bicolor)
  • Soybean (Glycine max)
  • Stem Rust Fungus (Puccinia graminis)
  • Sugarcane (Saccharum officinarum)
  • Thale Cress (Arabidopsis thaliana)
  • Tomato (Lycopersicon esculentum)
  • Toxoplasmosis (Toxoplasma gondii)
  • Trichoplax (Trichoplax adhaerens)
  • Wheat (Triticum aestivum)

Evolution for CYP3A4 Gene

ENSEMBL:
Gene Tree for CYP3A4 (if available)
TreeFam:
Gene Tree for CYP3A4 (if available)
Aminode:
Evolutionary constrained regions (ECRs) for CYP3A4: view image

Paralogs for CYP3A4 Gene

Paralogs for CYP3A4 Gene

(14) SIMAP similar genes for CYP3A4 Gene using alignment to 5 proteins:

  • CP3A4_HUMAN
  • C9JBD2_HUMAN
  • E7EVM8_HUMAN
  • Q6GRK0_HUMAN
  • Q7Z448_HUMAN

Pseudogenes.org Pseudogenes for CYP3A4 Gene

genes like me logo Genes that share paralogs with CYP3A4: view

Variants for CYP3A4 Gene

Products:

  1. SNP Genotyping and Copy Number Assay

Sequence variations, with clinical significance, from ClinVar and Humsavar, with links to dbSNP for CYP3A4 Gene

SNP ID Clinical significance and condition Chr 07 pos Variation AA Info Type
670902 Likely Benign: not provided 99,762,206(-) G/A MISSENSE_VARIANT
768183 Benign: not provided 99,768,445(-) G/A SYNONYMOUS_VARIANT
774657 Benign: not provided 99,762,032(-) G/A INTRON_VARIANT
rs2740574 Drug Response: CYP3A4 PROMOTER POLYMORPHISM; Cyp3a4-v; tacrolimus response - Dosage 99,784,473(-) C/T
rs765598920 Uncertain Significance: not specified 99,758,182(-) G/T MISSENSE_VARIANT

Additional dbSNP identifiers (rs#s) for CYP3A4 Gene

Structural Variations from Database of Genomic Variants (DGV) for CYP3A4 Gene

Variant ID Type Subtype PubMed ID
nsv482109 CNV gain 20164927
nsv970558 CNV duplication 23825009
nsv981555 CNV duplication 23825009

Variation tolerance for CYP3A4 Gene

Residual Variation Intolerance Score: 79.2% of all genes are more intolerant (likely to be disease-causing)
Gene Damage Index Score: 1.94; 35.96% of all genes are more intolerant (likely to be disease-causing)

Additional Variant Information for CYP3A4 Gene

The Human Cytochrome P450 Allele Nomenclature Database
CYP3A4
Human Gene Mutation Database (HGMD)
CYP3A4
SNPedia medical, phenotypic, and genealogical associations of SNPs for
CYP3A4

No data available for Polymorphic Variants from UniProtKB/Swiss-Prot for CYP3A4 Gene

Disorders for CYP3A4 Gene

MalaCards: The human disease database

(81) MalaCards diseases for CYP3A4 Gene - From: DISEASES, Novoseek, and GeneCards

Disorder Aliases PubMed IDs
acetaminophen metabolism
drug allergy
  • allergy drug
diarrhea
  • diarrhea of presumed infectious origin
anxiety
  • anxiety disorder
rhinitis
  • runny nose
- elite association - COSMIC cancer census association via MalaCards

Additional Disease Information for CYP3A4

Genetic Association Database
(GAD)
Human Genome Epidemiology Navigator
(HuGE)
ATLAS of Genetics and Cytogenetics in Oncology and Haematology
Open Targets Platform
genes like me logo Genes that share disorders with CYP3A4: view

No data available for UniProtKB/Swiss-Prot and Genatlas for CYP3A4 Gene

Publications for CYP3A4 Gene

  1. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. (PMID: 19934400) Lamba V … Schuetz EG (The Journal of pharmacology and experimental therapeutics 2010) 3 23 41
  2. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. (PMID: 19424794) MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (Breast cancer research and treatment 2010) 3 23 41
  3. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. (PMID: 19784640) Zhang W … Zhang J (European journal of clinical pharmacology 2010) 3 23 41
  4. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. (PMID: 19802823) Becker ML … Stricker BH (Pharmacoepidemiology and drug safety 2010) 3 23 41
  5. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. (PMID: 20068078) van der Bol JM … de Jong FA (Clinical cancer research : an official journal of the American Association for Cancer Research 2010) 3 23 41

ExternalLinks

View latest publications for CYP3A4 gene in Mastermind

Products for CYP3A4 Gene